Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Current trials with amyloid antibodies have not shown clinical benefit, but the results suggest that treating patients earlier in the course, or during the presymptomatic period, might be beneficial.

Monoclonal Amyloid Antibodies for the Treatment of Alzheimer’s Disease: More Disappointment